[go: up one dir, main page]

MXPA06000933A - Compuestos de aminopirazol y uso como inhibidores de chk1. - Google Patents

Compuestos de aminopirazol y uso como inhibidores de chk1.

Info

Publication number
MXPA06000933A
MXPA06000933A MXPA06000933A MXPA06000933A MXPA06000933A MX PA06000933 A MXPA06000933 A MX PA06000933A MX PA06000933 A MXPA06000933 A MX PA06000933A MX PA06000933 A MXPA06000933 A MX PA06000933A MX PA06000933 A MXPA06000933 A MX PA06000933A
Authority
MX
Mexico
Prior art keywords
compounds
methods
chk1 inhibitors
aminopyrazole
aminopyrazole compounds
Prior art date
Application number
MXPA06000933A
Other languages
English (en)
Inventor
Jinjiang Zhu
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MXPA06000933A publication Critical patent/MXPA06000933A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Health & Medical Sciences (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En este documento se describen compuestos de aminopirazol de formula I: (ver formula (I)) en la que R1, R2, L y Ar son como se han definido en esta memoria descriptiva; tales compuestos son capaces de modular la actividad de una cinasa punto de control y los metodos para utilizar tal modulacion para tratar trastornos proliferativos celulares; tambien se describen composiciones farmaceuticas que contienen tales compuestos, tambien se describe el uso terapeutico o profilactico de tales compuestos y composiciones, y metodos para tratar el cancer asi como otras enfermedades asociadas con proliferacion celular no deseada, administrando cantidades eficaces de tales compuestos en combinacion con agentes anti-neoplasicos.
MXPA06000933A 2003-07-25 2004-07-14 Compuestos de aminopirazol y uso como inhibidores de chk1. MXPA06000933A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48997603P 2003-07-25 2003-07-25
PCT/IB2004/002397 WO2005009435A1 (en) 2003-07-25 2004-07-14 Aminopyrazole compounds and use as chk1 inhibitors

Publications (1)

Publication Number Publication Date
MXPA06000933A true MXPA06000933A (es) 2006-03-30

Family

ID=34102954

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06000933A MXPA06000933A (es) 2003-07-25 2004-07-14 Compuestos de aminopirazol y uso como inhibidores de chk1.

Country Status (6)

Country Link
US (1) US20050043381A1 (es)
JP (1) JP2006528661A (es)
BR (1) BRPI0412820A (es)
CA (1) CA2532231A1 (es)
MX (1) MXPA06000933A (es)
WO (1) WO2005009435A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
ES2525217T3 (es) * 2005-06-27 2014-12-19 Exelixis Patent Company Llc Moduladores de LXR basados en imidazol
CN101248048B (zh) * 2005-06-27 2013-08-28 埃克塞利希斯专利有限责任公司 吡唑基lxr调节剂
DE102005035741A1 (de) * 2005-07-29 2007-02-08 Merck Patent Gmbh Quadratsäurederivate
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
US9000027B2 (en) * 2008-02-04 2015-04-07 Dana-Farber Cancer Institute, Inc. Chk1 suppresses a caspase-2 apoptotic response to DNA damage that bypasses p53, bcl-2 and caspase-3
US8314108B2 (en) 2008-12-17 2012-11-20 Eli Lilly And Company 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile, pharmaceutically acceptable salts thereof, or solvate of salts
PA8850801A1 (es) * 2008-12-17 2010-07-27 Lilly Co Eli Compuestos útiles para inhibir chk1
AR083575A1 (es) * 2010-11-08 2013-03-06 Lilly Co Eli Aminopirazoles para inhibir la proteinquinasa chk1
EP2800754B1 (en) * 2011-12-19 2017-06-28 Saudi Basic Industries Corporation (Sabic) Process for the preparation of metallocene complexes
US9234054B2 (en) * 2011-12-19 2016-01-12 Saudi Basic Industries Corporation Process for the preparation of metallocene complexes
CN103275010A (zh) * 2013-05-30 2013-09-04 上海皓元生物医药科技有限公司 一种1-(3-甲基-1-苯基-1h-吡唑-5-基)哌嗪的制备方法
AU2014293011A1 (en) 2013-07-26 2016-03-17 Race Oncology Ltd. Compositions to improve the therapeutic benefit of bisantrene
GB201402277D0 (en) * 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
EP3411036B1 (en) * 2016-02-04 2021-12-29 Pharmaengine, Inc. 3,5-disubstituted pyrazoles useful as checkpoint kinase 1 (chk1) inhibitors, and their preparations and applications
BR112018068681A2 (pt) 2016-03-16 2019-01-15 Bayer Cropscience Ag derivados de n-(cianobenzil)-6-(ciclopropil-carbonilamino)-4-(fenil)-piridina-2-carboxamida e compostos relacionados como pesticidas e agentes de proteção de plantas
EP3568395A1 (de) 2017-01-10 2019-11-20 Bayer Aktiengesellschaft Heterocyclen-derivate als schädlingsbekämpfungsmittel
KR20190130621A (ko) 2017-03-31 2019-11-22 시애틀 지네틱스, 인크. Chk1 저해제와 wee1 저해제의 조합물
EP3284739A1 (de) 2017-07-19 2018-02-21 Bayer CropScience Aktiengesellschaft Substituierte (het)arylverbindungen als schädlingsbekämpfungsmittel
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
EP3749648B1 (en) 2018-02-07 2024-10-30 Korea Research Institute of Chemical Technology N-(phenyl)-5-(phenyl)-1h-pyrazol-3-amine derivatives as tnik inhibitors for use in the treatment of cancer
AU2019260016B2 (en) 2018-04-25 2022-11-17 Bayer Aktiengesellschaft Novel heteroaryl-triazole and heteroaryl-tetrazole compounds as pesticides
US20220041591A1 (en) * 2018-10-19 2022-02-10 Auckland Uniservices Limited Compounds for treating diabetes and/or related conditions
CN111072652B (zh) * 2018-10-19 2023-05-23 暨南大学 用于治疗糖尿病和/或相关病症的化合物
UY38696A (es) 2019-05-14 2020-11-30 Vertex Pharma Moduladores de alfa-1 antitripsina
CN112457306A (zh) 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
TW202136248A (zh) 2019-11-25 2021-10-01 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基-三唑化合物
CN114746413B (zh) 2019-11-29 2024-02-23 南京明德新药研发有限公司 二氮杂吲哚类衍生物及其作为Chk1抑制剂的应用
WO2021119236A1 (en) 2019-12-10 2021-06-17 Seagen Inc. Preparation of a chk1 inhibitor compound
US12502376B2 (en) 2020-04-03 2025-12-23 Vertex Pharmaceuticals Incorporated Pyrano[4,3-b]indole derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (AATD)
TWI891782B (zh) 2020-05-06 2025-08-01 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基三唑化合物
KR20240005019A (ko) 2021-05-06 2024-01-11 바이엘 악티엔게젤샤프트 알킬아미드 치환된, 환형 이미다졸 및 살충제로서의 이의 용도
GB202107924D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd A pharmaceutical salt
GB202107932D0 (en) 2021-06-03 2021-07-21 Sentinel Oncology Ltd Preparation of a CHK1 Inhibitor Compound
EP4392419B1 (en) 2021-08-25 2025-07-23 Bayer Aktiengesellschaft Novel pyrazinyl-triazole compounds as pesticides
EP4455134A4 (en) * 2021-12-24 2025-10-08 Sumitomo Pharma Co Ltd 1H-PYRAZOLE-3-AMINE DERIVATIVE HAVING A BICYCLIC SKELETON
EP4532492A1 (en) * 2022-05-25 2025-04-09 Sperogenix Therapeutics Limited Nitrogen-containing five-membered heterocyclic derivatives as checkpoint kinase 1 inhibitor and uses thereof
WO2025186065A1 (en) 2024-03-05 2025-09-12 Bayer Aktiengesellschaft Heteroaryl-substituted (aza)quinoxaline derivatives as pesticides

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2219670T3 (es) * 1994-11-10 2004-12-01 Millennium Pharmaceuticals, Inc. Utilizacion de compuestos de pirazola para el tratamiento de la glomerulonefritis, cancer, ateroesclerosis o restenosis.
US6235769B1 (en) * 1997-07-03 2001-05-22 Sugen, Inc. Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase
US6368831B1 (en) * 1998-06-29 2002-04-09 Childrens Hospital Los Angeles Treatment of hyperproliferative disorders
CA2381882C (en) * 1999-08-13 2011-01-25 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
CA2398446A1 (en) * 2000-04-18 2001-10-25 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases
CZ2003468A3 (cs) * 2000-08-31 2004-05-12 Pfizeráproductsáinc Deriváty pyrazolu a jejich použití jako inhibitorů proteinkinázy

Also Published As

Publication number Publication date
CA2532231A1 (en) 2005-02-03
WO2005009435A1 (en) 2005-02-03
JP2006528661A (ja) 2006-12-21
US20050043381A1 (en) 2005-02-24
BRPI0412820A (pt) 2006-09-26

Similar Documents

Publication Publication Date Title
MXPA06000933A (es) Compuestos de aminopirazol y uso como inhibidores de chk1.
PH12022552739A1 (en) Fused tricyclic kras inhibitors
TW200510380A (en) Mitotic kinesin inhibitors
BRPI0416981A (pt) compostos para tratamento de doenças proliferativas de célula
PT1664026E (pt) Inibidores de cinesina mitótica
IL165624A0 (en) Mitotic kinesin inhibitors
EA200600209A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,4-c]ПИРАЗОЛА, ОБЛАДАЮЩИЕ АКТИВНОСТЬЮ КАК ИНГИБИТОРЫ КИНАЗЫ
TNSN08278A1 (en) Triazolopyridazines as tyrosine kinase modulators
NO20071428L (no) Kombinasjon inneholdende ZD6474 og Imatinib
YU61402A (sh) Pirol substituisani 2 indolinon protein kinazni inhibitori
EP1481077A4 (en) MITOTIC KINESINE HEMMER
UA94097C2 (ru) Пиридил- и пиримидинилзамещенные производной пиррола, тиофена и фурана как ингибиторы киназ
MY191349A (en) New pharmaceutical compositions for the treatment of hyper-proliferative disorders
TNSN08078A1 (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
IL181987A0 (en) Diaminotriazole derivatives and pharmaceutical compositions containing the same
MX2007003603A (es) Metodos para preparar compuestos de indazol.
ATE439134T1 (de) Medikament zum schutz in der radiotherapie
WO2005004808A3 (en) TETRACYCLIC COMPOUNDS AS c-MET INHIBITORS
EA200800011A1 (ru) Тиенопиримидиновые и тиенопиридиновые модуляторы киназы
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
ATE419249T1 (de) Inhibitoren von mitotischem kinesin
ATE426605T1 (de) Inhibitoren von mitotischem kinesin
EP1511713B8 (en) Compounds that abrogate dna-damage-induced cell cycle g2 checkpoint and/or augment the anti-cancer activity of dna-damaging treatments
ATE482218T1 (de) Inhibitoren von mitotischem kinesin
MX2022015493A (es) Compuestos de imidazopiridazina y usos de los mismos.